



Formulary Updates for Advanced Control Choice Formulary® effective October 1, 2026

The changes to Zepbound and Foundayo were previously communicated; additional changes are included here.

Products to be **added** to the formulary:

Formulary Additions

Drug Class	Product(s) Added
Endocrine and Metabolic, Antiobesity	ZEPBOUND

These products will move **from non-preferred to preferred**:

Tier Changes: Non-Preferred to Preferred

Drug Class	Product Name(s)
Antineoplastic Agents, Kinase Inhibitors	KOSELUGO ORAL GRANULES
Endocrine and Metabolic, Antiobesity	FOUNDAYO

Products that will be **removed** from the formulary:

Formulary Removals

Drug Class	Removed Product(s)	Formulary Options
Autoimmune Agents, Self-Administered	XELJANZ*, XELJANZ XR*	<u>Ankylosing Spondylitis**</u> : tofacitinib, tofacitinib ext-rel, ADALIMUMAB-ADAZ, COSENTYX SC, ENBREL, HUMIRA, HYRIMOZ (by Cordavis), RINVOQ <u>Psoriatic Arthritis**</u> : tofacitinib, tofacitinib ext-rel, ADALIMUMAB-ADAZ, COSENTYX SC, ENBREL, HUMIRA, HYRIMOZ (by Cordavis), OTEZLA, OTEZLA XR, PYZCHIVA SC (by Cordavis), RINVOQ, SKYRIZI SC, TREMFYA SC, YESINTEK SC <u>Rheumatoid Arthritis</u> : tofacitinib, tofacitinib ext-rel, ADALIMUMAB-ADAZ, ENBREL, HUMIRA, HYRIMOZ (by Cordavis), KEVZARA, ORENCIA CLICKJECT, ORENCIA SC, RINVOQ <u>Ulcerative Colitis</u> : tofacitinib, tofacitinib ext-rel, ADALIMUMAB-ADAZ, ENTYVIO SC, HUMIRA, HYRIMOZ (by Cordavis), PYZCHIVA SC (by Cordavis), RINVOQ, SKYRIZI SC, TREMFYA SC, VELSIPITY, YESINTEK SC, ZEPOSIA
Nutritional/Supplements, Prenatal Vitamins	INTAL GT, PRENATAL 19, TRINATE	generic prenatal vitamins

These products will move **from preferred to non-preferred**:

Tier Changes: Preferred to Non-Preferred

Drug Class	Product Name(s)	Formulary Options
Antidiabetics, Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors	FARXIGA*	<i>dapagliflozin</i> , JARDIANCE
Antidiabetics, Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor Combinations	XIGDUO XR* (except 2.5-1000mg)	<i>dapagliflozin-metformin ext-rel</i> , SYNJARDY, SYNJARDY XR
Central Nervous System, Antiseizure Agents	BRIVIACT*	<i>brivaracetam, carbamazepine, carbamazepine ext-rel, divalproex sodium, divalproex sodium ext-rel, eslicarbazepine, gabapentin, lacosamide, lamotrigine, lamotrigine ext-rel, levetiracetam, levetiracetam ext-rel, oxcarbazepine, oxcarbazepine ext-rel, phenobarbital, phenytoin, phenytoin sodium extended, pregabalin, primidone, tiagabine, topiramate, topiramate ext-rel, valproic acid, zonisamide</i> , OXTELLAR XR, XCOPRI

Indication-Based Strategy Updates

Drug Class	Target Product(s)	Formulary Options
Psoriatic Arthritis	SOTYKTU	<i>tofacitinib, tofacitinib ext-rel</i> , ADALIMUMAB-ADAZ, COSENTYX SC, ENBREL, HUMIRA, HYRIMOZ (by Cordavis), OTEZLA, OTEZLA XR, PYZCHIVA SC (by Cordavis), RINVOQ, SKYRIZI SC, TREMFYA SC, YESINTEK SC

UPPERCASE represents brand products

lowercase represents generic products

**XELJANZ, XELJANZ XR currently excluded for Ankylosing Spondylitis and Psoriatic Arthritis

^Previously New to Market Block

*Multi-source Brand Product

This chart contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Health and/or one of its affiliates. Information listed is current as of July 1, 2026 and subject to change.